In the past year, the development of new tuberculosis (TB) drug candidates experienced some setbacks as well as some wise pruning, with the unexpected suspension of enrollment in STAND (a phase III combination trial that includes the new drug pretomanid), the discontinuation of candidate TBA-354 (due to signs of toxicity), and the official end of development of AZD5847 (due to lack of anti-TB activity). In a bright spot, Qurient's Q203 entered phase I, representing a new drug class and a new sponsor in TB clinical trials. But overall, the new TB drug development landscape remains parched, with just five candidates from four classes in development—including bedaquiline and delamanid, which already have conditional marketing approval in some countries. Most of these drugs have been stalled for years. Delays across the board, from sponsors, from regulators, and from funders, are preventing nascent progress from flourishing. The phase III trial for bedaquiline has finally started enrolling—some five years after the phase IIb trial concluded. Sutezolid is still awaiting entry into phase IIb, nearly five years after showing promise in phase IIa. Delamanid's phase III trial is chugging along dutifully, but, due to the lengthy standard-of-care background treatment and follow-up time required in TB clinical studies, won't give results till 2018.